In a pooled analysis of 4 clinical trials that compared the efficacy of atezolizumab versus docetaxel in patients with advanced NSCLC, Kichenadasse et al. found that higher BMI is independently associated with better prognosis with atezolizumab, especially in patients with high expression of PD-L1 (31). This evidence concerns the gene CD274 and non-small cell lung carcinoma.